Skin Laboratory PCL (BKK:SKIN)
Thailand · Delayed Price · Currency is THB 1.010
+0.120 (13.48%)
At close: Sep 14, 2026
Skin Laboratory PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 149.04 | 176.73 | 229.13 | 271.8 | 282.12 | 197.55 |
Other Revenue | 1.79 | 2.23 | 1.4 | 0.99 | 0.58 | 1.03 |
| 150.83 | 178.96 | 230.53 | 272.8 | 282.7 | 198.57 | |
Revenue Growth | -25.34% | -22.37% | -15.49% | -3.50% | 42.37% | 17.80% |
Cost of Revenue | 43.72 | 49.53 | 57.5 | 63.23 | 70.65 | 65.56 |
Gross Profit | 107.11 | 129.43 | 173.03 | 209.56 | 212.05 | 133.02 |
Selling, General & Admin | 125.33 | 123.69 | 159.5 | 188.28 | 196.86 | 96.43 |
Operating Expenses | 125.33 | 123.69 | 159.5 | 188.28 | 196.86 | 96.43 |
Operating Income | -18.22 | 5.74 | 13.53 | 21.28 | 15.19 | 36.59 |
Interest Expense | -0.11 | -0.15 | -0.25 | -0.19 | -0.18 | -0.18 |
EBT Excluding Unusual Items | -18.33 | 5.59 | 13.28 | 21.1 | 15.01 | 36.41 |
Gain (Loss) on Sale of Investments | - | - | 0.25 | -0.07 | - | - |
Pretax Income | -18.33 | 5.59 | 13.53 | 21.02 | 15.01 | 36.41 |
Income Tax Expense | -0.37 | 1.21 | 2.86 | 4.24 | 3.15 | 7.64 |
Net Income | -17.95 | 4.38 | 10.67 | 16.79 | 11.86 | 28.77 |
Net Income to Common | -17.95 | 4.38 | 10.67 | 16.79 | 11.86 | 28.77 |
Net Income Growth | - | -58.97% | -36.44% | 41.59% | -58.80% | 0.10% |
Shares Outstanding (Basic) | 135 | 113 | 43 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 135 | 113 | 43 | 2 | 2 | 2 |
Shares Change | 46.42% | 162.19% | 2048.36% | - | - | - |
EPS (Basic) | -0.13 | 0.04 | 0.25 | 8.39 | 5.93 | 14.39 |
EPS (Diluted) | -0.13 | 0.04 | 0.25 | 8.39 | 5.93 | 14.39 |
EPS Growth | - | -84.35% | -97.04% | 41.59% | -58.80% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -19.34 | 11.97 | 3.57 | 26.25 | 4.62 | 10.87 |
Free Cash Flow Per Share | -0.14 | 0.11 | 0.08 | 13.12 | 2.31 | 5.43 |
Dividend Per Share | - | - | 27.580 | 7.500 | 8.000 | 6.830 |
Dividend Growth | - | - | 267.73% | -6.25% | 17.13% | 1.19% |
Gross Margin | 71.01% | 72.32% | 75.06% | 76.82% | 75.01% | 66.98% |
Operating Margin | -12.08% | 3.21% | 5.87% | 7.80% | 5.37% | 18.42% |
Profit Margin | -11.90% | 2.45% | 4.63% | 6.15% | 4.19% | 14.49% |
Free Cash Flow Margin | -12.82% | 6.69% | 1.55% | 9.62% | 1.63% | 5.47% |
EBITDA | -18.39 | 6.2 | 14.43 | 21.62 | 15.61 | 37.03 |
EBITDA Margin | -12.19% | 3.47% | 6.26% | 7.93% | 5.52% | 18.65% |
D&A For EBITDA | -0.17 | 0.46 | 0.9 | 0.34 | 0.42 | 0.44 |
EBIT | -18.22 | 5.74 | 13.53 | 21.28 | 15.19 | 36.59 |
EBIT Margin | -12.08% | 3.21% | 5.87% | 7.80% | 5.37% | 18.42% |
Effective Tax Rate | - | 21.72% | 21.16% | 20.16% | 20.99% | 20.97% |
Revenue as Reported | 150.83 | 178.96 | 230.53 | 272.8 | 282.7 | 198.57 |
Advertising Expenses | - | 89.63 | 123.68 | 150.16 | - | 48.6 |